Global Acute Migraine Drugs Market 2022 Future Analysis – Teva Pharmaceutical, Pfizer Inc., Novartis AG, Merck & Co

Market Snapshot

Need a report that reflects how COVID-nineteen has impacted this market and its growth?

Market Overview

The migraine therapeutics marketplace is expected to register a CAGR of ix.5% during the forecast period (2022-2027).

COVID-19 was a global public health crunch, and it impacted most every manufacture, and its long-term furnishings were expected to touch on manufacture growth over the forecast catamenia. Co-ordinate to the report titled “Bear upon of COVID-19 pandemic on migraine management in the Us: insights from migraine tracking app users” published in BMC neurology in September 2021, although the number of migraine attacks decreased, the proportion of stress-related migraine attacks peaked at 53% during COVID-19. Also, the written report titled “COVID‐xix and Headache Medicine: A Narrative Review of NonSteroidal AntiInflammatory Drug (NSAID) and Corticosteroid Utilize” published in July 2021, reported that there may be an increase in the number of patients with headaches as their main complaint during the COVID19 pandemic. Hence, COVID-19 had a significant impact on the migraine therapeutics marketplace.

Growing awareness most migraine and treatment options, rising R&D spending leading to massive pipeline products, and an increase in the prevalence of migraines with high unmet needs are all contributing to the global growth of the migraine therapeutics market.

The various strategic activities by the key market place players, such every bit product launches and product approvals, also as mergers and acquisitions, boost the market place over the forecast period. For instance, in March 2022, AbbVie reported a positive stage 3 progress trial evaluating atogepant (QULIPTA in the U.s.a.) for the preventive treatment of chronic migraine in adults. Information technology is an oral calcitonin factor-related peptide (CGRP) receptor antagonist (gepant). In the trial, the drug met its primary endpoint of a statistically pregnant reduction from baseline in hateful monthly migraine days compared to placebo, for both the 60 mg one time daily (QD) and xxx mg twice daily (BID) doses, across the 12-week treatment menstruum.

Additionally, in September 2021, the United States Nutrient and Drug Administration (FDA) approved QULIPTA (atogepant) to AbbVie for the prevention of episodic migraine in adults. QULIPTA is one of the globe’s outset and just oral calcitonin gene-related peptide (CGRP) receptor antagonists (gepant) developed specifically for migraine prevention.

Thus, the market is expected to projection growth over the forecast menstruation. Even so, the growth of the migraine therapeutics market may be hampered due to a lack of proper diagnosis, undiagnosed cases, and drug side effects over the forecast menses.

Telescopic of the Study

Every bit per the telescopic of the report, migraine is a complex neurological condition characterized by frequent headaches that can last from 4 to 72 hours. The pain is often unilateral and pulsating in nature, which can frequently be worsened by concrete activeness. In most cases, migraine is associated with symptoms such as photophobia, phonophobia, osmophobia, nausea, vomiting, loss of appetite, and sometimes sensory disturbances. The Migraine Therapeutics Marketplace is segmented by Therapeutics (Hurting-relieving Medications (Analgesics, Triptans, Ergot Alkaloids, Others), and Preventive Medications (Blood pressure-lowering Medications, Anticonvulsant Drugs, Calcitonin Factor-related Peptide (CGRP) Antagonists, Other Preventative Therapies)), Route of Assistants (Oral & Nasal and Injectables), and Geography (Northward America, Europe, Asia-Pacific, Centre E & Africa, and South America). The report also covers the estimated market sizes and trends for 17 countries beyond major regions globally. The report offers the value (in USD one thousand thousand) for the above segments.

By Therapeutics
Pain-relieving Medications
Analgesics
Triptans
Ergot Alkaloids
Others
Preventive Medications
Blood pressure-lowering Medications
Anticonvulsant Drugs
Calcitonin Factor-related Peptide (CGRP) Antagonists
Other Preventative Therapies
By Route of Administration
Oral & Nasal
Injectables
Geography
N America
United States
Canada
Mexico
Europe
Federal republic of germany
Britain
France
Italia
Spain
Rest of Europe
Asia-Pacific
China
Nihon
Bharat
Commonwealth of australia
S Korea
Residual of Asia-Pacific
Center-Eastward and Africa
GCC
S Africa
Residual of Eye-Due east and Africa
South America
Brazil
Argentina
Rest of South America

Written report scope tin can be customized per your requirements. Click here.

Key Market Trends

The Triptans Segment Is Expected to Grow at a Good for you CAGR Over the Forecast Menses

Triptans are a newer course of drug that increases serotonin levels in the brain, reducing inflammation and constricting blood vessels, finer ending a migraine. Triptans tuck claret vessels in the brain and block pain pathways. These ergotamines are more migraine-specific than previous ergotamines. Almotriptan (Axert), eletriptan (Relpax), frovatriptan (Frova), naratriptan (Amerge), rizatriptan (Maxalt, Maxalt-MLT), sumatriptan (Imitrex), sumatriptan and naproxen (Treximet), and zolmitriptan (Zomig) are some of the triptans available. Sumatriptan and naproxen sodium (Treximet), a unmarried-tablet combination, are more than effective than either medication lone in alleviating migraine symptoms.

Furthermore, as per the report titled “Comparison of New Pharmacologic Agents With Triptans for Treatment of Migraine” published in JAMA Network in Oct 2020, ditans and gepants were associated with less efficacy compared with triptans, whereas gepants were associated with fewer adverse events compared with triptans. Thus, due to the higher efficacy of the triptans, at that place is expected to be a ascent in demand for them, thereby boosting the segment over the forecast period.

Moreover, the product launches and market place approvals for drugs in the triptan class are also driving the growth of the market place segment. For instance, in January 2020, Eli Lilly and Company launched the REYVOW (lasmiditan) C-Five 50 mg and 100 mg tablets. Information technology is an oral medication for the acute handling of migraine with or without aura in adults.

Thus, owing to the aforementioned factors such as the higher efficacy of triptan and new production launches, the market segment is expected to boost the market over the forecast catamenia.

Migraine Therapeutics Market - Estimates of Funding for Research and Development of Migraine (in USD million), United States, 2020 - 2022

North America is Expected to Concord a Pregnant Share Over the Forecast Flow

North America is expected to boss the overall market and is projected to maintain its dominance over the coming years. The high prevalence of migraine, the increasing adoption of novel therapeutics, and the large target population in the United States are the factors that contribute to the region’s dominance.

According to the article titled “What is Migraine?” published in the JAMA Network in Jan 2022, in the United States, 17.one% of women and 5.half dozen% of men reported having migraine symptoms. Thus, such a high prevalence is expected to boost the migraine therapeutics marketplace in the Usa.

Additionally, various strategic activities by key market players, such as production launch and approval, as well equally mergers and acquisitions, will boost the market growth. For instance, in February 2020, Lundbeck received VYEPTI (eptinezumab-jjmr) approval by the United states of america Food and Drug Administration (FDA) for the preventive treatment of migraine in adults. Furthermore, in May 2021, Biohaven Pharmaceutical Holding Company Ltd. received U.s.a. Nutrient and Drug Administration (FDA) approving for NURTEC ODT (rimegepant 75 mg) for the preventive treatment of migraine. NURTEC ODT is indicated for adult patients with episodic migraine, e.g., those who feel fewer than 15 headache days per month. Such approvals propel the growth of the studied market over the forecast period.

Thus, owing to the abovementioned factors, the North American region is expected to dominate the market over the forecast period.

Global Acute Migraine Drugs Market 2022 Future Analysis – Teva Pharmaceutical, Pfizer Inc., Novartis AG, Merck & Co

Competitive Landscape

The migraine therapeutics market is moderately fragmented with the presence of a large number of local and international players. Key players are adopting different growth strategies to enhance their market presence, such as partnerships, agreements, collaborations, new product launches, geographical expansions, mergers, and acquisitions. Some of the key market place players include Amgen, Teva Pharmaceutical, Eli Lilly and Company, and GlaxoSmithKline plc, among others.

Major Players

  1. Amgen
  2. Teva Pharmaceutical Industries Ltd
  3. GlaxoSmithKline
  4. Eli Lilly and Company
  5. Bausch Health
Migraine Therapeutics Market Concentration

Table of Contents

  1. one. INTRODUCTION
    1. 1.i Report Assumptions and Market place Definition
    2. 1.2 Telescopic of the Written report
  2. 2. Inquiry METHODOLOGY
  3. 3. EXECUTIVE SUMMARY
  4. 4. MARKET DYNAMICS
    1. 4.1 Market Overview
    2. 4.2 Market Drivers
      1. 4.2.ane Growing Sensation about Migraine and its Handling Options
      2. 4.2.two Increasing R&D Expenditures Leading to High Pipeline Products
      3. iv.two.3 Increasing Prevalence of Migraines along with High Unmet Needs
    3. 4.3 Market place Restraints
      1. 4.3.1 Adverse Effects of Drugs
      2. 4.3.two Lack of Proper Diagnosis and Increasing Undiagnosed Cases
    4. 4.4 Porter’s Five Forces Assay
      1. 4.four.one Threat of New Entrants
      2. 4.4.ii Bargaining Power of Buyers/Consumers
      3. four.iv.three Bargaining Ability of Suppliers
      4. iv.4.four Threat of Substitute Products
      5. iv.4.5 Intensity of Competitive Rivalry
  5. 5. Market Division (Marketplace Size past Value – USD meg)
    1. five.1 By Therapeutics
      1. 5.1.1 Hurting-relieving Medications
        1. 5.1.1.ane Analgesics
        2. v.one.1.two Triptans
        3. 5.i.1.3 Ergot Alkaloids
        4. v.1.one.4 Others
      2. 5.1.ii Preventive Medications
        1. 5.1.two.1 Blood pressure-lowering Medications
        2. 5.1.2.2 Anticonvulsant Drugs
        3. 5.1.2.3 Calcitonin Gene-related Peptide (CGRP) Antagonists
        4. 5.one.2.four Other Preventative Therapies
    2. 5.2 By Route of Administration
      1. five.ii.1 Oral & Nasal
      2. v.2.two Injectables
    3. 5.three Geography
      1. 5.3.1 Northward America
        1. v.iii.1.1 The states
        2. 5.3.1.2 Canada
        3. 5.three.1.three Mexico
      2. 5.3.2 Europe
        1. 5.3.2.1 Germany
        2. five.3.2.2 United Kingdom
        3. 5.3.2.3 France
        4. 5.3.2.4 Italy
        5. 5.3.2.five Kingdom of spain
        6. 5.iii.ii.6 Rest of Europe
      3. 5.three.iii Asia-Pacific
        1. 5.3.3.i Red china
        2. 5.three.3.2 Nippon
        3. 5.3.iii.3 India
        4. 5.three.iii.4 Australia
        5. 5.3.three.5 South korea
        6. five.three.three.6 Rest of Asia-Pacific
      4. five.3.4 Eye-East and Africa
        1. v.3.4.1 GCC
        2. 5.3.4.2 South Africa
        3. 5.3.4.iii Rest of Middle-Eastward and Africa
      5. 5.3.5 South America
        1. v.3.five.i Brazil
        2. five.3.five.two Argentine republic
        3. 5.3.five.three Balance of Southward America
  6. half dozen. COMPETITIVE Mural
      1. 6.1 Company Profiles
        1. vi.1.ane Amgen
        2. 6.1.ii Abbvie Inc.
        3. 6.1.3 AstraZeneca
        4. six.1.4 Eli Lilly and Co.
        5. 6.1.5 GlaxoSmithKline
        6. 6.one.6 Merck & Co., Inc.
        7. 6.1.vii Pfizer
        8. half dozen.1.8 Bausch Health
        9. vi.1.nine Teva Pharmaceuticals
        10. half-dozen.1.10 Novartis AG
        11. 6.1.11 Eisai Co., Ltd.,
        12. 6.1.12 Abbott Laboratories

    *List Not Exhaustive

  7. 7. MARKET OPPORTUNITIES AND Future TRENDS

**Subject to Availability

**Competitive Landscape Covers – Business concern Overview, Financials, Products and Strategies, and Contempo Developments

You tin can also buy parts of this report. Practice you desire to check out a section wise price list?

Oftentimes Asked Questions

What is the study period of this marketplace?

The Global Migraine Therapeutics Market place market is studied from 2019 – 2027.

What is the growth rate of Global Migraine Therapeutics Market?

The Global Migraine Therapeutics Market place is growing at a CAGR of nine.v% over the next v years.

Which region has highest growth rate in Global Migraine Therapeutics Market?

Asia Pacific is growing at the highest CAGR over 2021- 2026.

Which region has largest share in Global Migraine Therapeutics Market?

North America holds highest share in 2021.

Who are the primal players in Global Migraine Therapeutics Market place?

Amgen, Teva Pharmaceutical Industries Ltd, GlaxoSmithKline, Eli Lilly and Company, Bausch Health are the major companies operating in Global Migraine Therapeutics Market.


fourscore%
of our clients seek made-to-lodge reports. How do you desire united states to tailor yours?

Source: https://www.mordorintelligence.com/industry-reports/migraine-therapeutics-market

Check Also

Masimo (MASI) W1 Watch With Hi to Improve Patient Outcome

Also Available, in Limited Market Release, Is Masimo W1 with Hydration Index, Designed to Provide …